Relationship of carbohydrate metabolism indicators during adjuvant radiotherapy and survival in patients with glioblastoma

Balkanov A.S.; Rozanov I.D.; Glazkov A.A.

doi:https://doi.org/10.17116/neiro20228605113

Balkanov A.S.

Vladimirsky Moscow Regional Research Clinical Institute

ORCID: 0000-0002-1601-9780

Rozanov I.D.

Botkin Moscow City Clinical Hospital

ORCID: 0000-0003-0626-5272

Glazkov A.A.

Moscow Regional Research and Clinical Institute

Relationship of carbohydrate metabolism indicators during adjuvant radiotherapy and survival in patients with glioblastoma

Authors:

Balkanov A.S., Rozanov I.D., Glazkov A.A.

More about the authors

Journal: Burdenko's Journal of Neurosurgery. 2022;86(5): 13‑20

DOI: 10.17116/neiro20228605113

Read: 3376 times

To cite this article:

Balkanov AS, Rozanov ID, Glazkov AA. Relationship of carbohydrate metabolism indicators during adjuvant radiotherapy and survival in patients with glioblastoma. Burdenko's Journal of Neurosurgery. 2022;86(5):13‑20. (In Russ., In Engl.)
https://doi.org/10.17116/neiro20228605113

Подписка 2025 Журнал «Вопросы нейрохирургии» имени Н.Н. Бурденко (Burdenko's Journal of Neurosurgery)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To study carbohydrate metabolism in patients with glioblastoma during adjuvant external beam radiation therapy and its impact on survival.

MATERIAL AND METHODS

The study included 66 patients with glioblastoma (Karnofsky score ≥80%) who underwent hypofractionated adjuvant external beam radiation therapy (single focal dose 2.5-3Gr). Patients received dexamethasone 4-8 mg daily throughout the entire course of irradiation.

RESULTS

High level of glycated hemoglobin (Hb_A1c) was observed in 33.3% of patients with glioblastoma undergoing irradiation. Cumulative survival was 17 months (95% CI 13.7-20.3). Two indicators had a significant negative impact on cumulative survival: age of patients (HR 1.04; 95% CI 1.01-1.08; p=0.02) and level of Hb_A1c (HR 1.94; 95% CI 1.23-3.06; p=0.005). Cumulative survival was significantly (p=0.022) higher in patients younger 53 years compared to older people (18 months and 14 months, respectively). Cumulative survival was 20 months among patients whose Hb_A1c did not exceed the upper reference value (<5.8%). Survival was higher (p=0.017) in these ones compared to patients with Hb_A1c ≥5.8% (13 months). According to multivariate Cox regression model, high Hb_A1c was the only significant negative predictor of cumulative survival (HR 3.35; 95% CI 1.14-9.81; p=0.027).

CONCLUSION

High Hb_A1c is unfavorable predictor of cumulative survival in patients with glioblastoma and Karnofski score ≥80% undergoing adjuvant hypofractionated irradiation regardless their age.

Keywords:

glioblastoma of the brain

adjuvant irradiation

age

glycated hemoglobin

cumulative survival

Authors:

Balkanov A.S.

Vladimirsky Moscow Regional Research Clinical Institute

ORCID: 0000-0002-1601-9780

Rozanov I.D.

Botkin Moscow City Clinical Hospital

ORCID: 0000-0003-0626-5272

Glazkov A.A.

Moscow Regional Research and Clinical Institute

Received:

29.11.2021

Accepted:

19.08.2022

Close metadata

References:

Balkanov AS, Savkova RF, Dudarova RG, Petrushkina NN, Kachkov IA, Ananyeva II. Some indicators of the incidence of CNS tumors residents of the Moscow region from 1998 to 2003. Neirokhirurgiya. 2007;(3):83-86.
Darefsky AS, King JT, Dubrow R. Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries. Cancer. 2012;118(8):2163-2172. https://doi.org/10.1002/cncr.26494
Derr RL, Ye X, Islas MU, Desideri S, Saudek CD, Grossman SA. Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma. Journal of Clinical Oncology. 2009;27:1082-1086. https://doi.org/10.1200/JCO.2008.19.1098
Link TW, Woodworth GF, Chaichana KL, Grossman SA, Mayer RS, Brem H, Weingart JD, Quinones-Hinojosa A. Hyperglycemia is independently associated with post-operative function loss in patients with primary eloquent glioblastoma. Journal of Clinical Neuroscience. 2012;19(7):996-1000. https://doi.org/10.1016/j.jocn.2011.09.031
Adeberg S, Bernhardt D, Foerster R, Bostel T, Koerber SA, Mohr A, Koelsche C, Rieken S, Debus J. The influence of hyperglycemia during radiotherapy on survival in patients with primary glioblastoma. Acta Oncologica. 2016;55:201-207. https://doi.org/10.3109/0284186X.2015.1043397
Balkanov AS, Makarenko MF, Polyakov PYu, Kachkov IA. Results of radiation therapy in the mode of hypofractionation in combination with lomustin in malignant brain gliomas. Burdenko’s Journal of Neurosurgery. 2005;3:14-16.
Welch MR, Grommes C. Retrospective analysis of the effects of steroid therapy and antidiabetic medication on survival in diabetic glioblastoma patients. CNS Oncology. 2013;2(3):237-246. https://doi.org/10.2217/cns.13.12
Dietrich J, Rao K, Pastorino S, Kesari S. Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Review of Clinical Pharmacology. 2011;4(2):233-242. https://doi.org/10.1586/ecp.11.1
Marina O, Suh JH, Reddy CA, Barnett GH, Vogelbaum MA, Peereboom DM, Stevens GH, Elinzano H, Chao S.T. Treatment outcomes for patients with glioblastoma multiforme and a low Karnofsky Performance Scale score on presentation to a tertiary care institution. Journal of Neurosurgery. 2011;115(2):220-229. https://doi.org/10.3171/2011.3.JNS10495
Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabetic Medicine. 2013;30(7):803-817. https://doi.org/10.1111/dme.12159
Silbernagel G, Grammer TB, Winkelmann BR, Boehm BO, März W. Glycated Hemoglobin Predicts All-Cause, Cardiovascular, and Cancer Mortality in People Without a History of Diabetes Undergoing Coronary Angiography. Diabetes Care. 2011;34(6):1355-1361. https://doi.org/10.2337/dc10-2010
Filippini G, Falcone C, Boiardi A, Broggi G, Bruzzone MG, Caldiroli D, Farina R, Farinotti M, Fariselli L, Finocchiaro G, Giombini S, Pollo B, Savoiardo M, Solero CL, Valsecchi MG. Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. Neuro-Oncology. 2008;10(1):79-87. https://doi.org/10.1215/15228517-2007-038
Tieu MT, Lovblom LE, McNamara MG, Mason W, Laperriere N, Millar BA, Ménard C, Kiehl TR, Perkins BA, Chung C. Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide. Journal of Neuro-Oncology. 2015;124(1):119-126. https://doi.org/10.1007/s11060-015-1815-0
McGirt MJ, Chaichana KL, Gathinji M, Attenello F, Than K, Ruiz AJ, Olivi A, Quiñones-Hinojosa A. Persistent outpatient hyperglycemia is independently associated with decreased survival after primary resection of malignant brain astrocytomas. Neurosurgery. 2008;63(2):286-291. https://doi.org/10.1227/01.NEU.0000315282.61035.48
Mayer A, Vaupel P, Struss HG, Giese A, Stockinger M, Schmidberger H. Strong adverse prognostic impact of hyperglycemic episodes during adjuvant chemoradiotherapy of glioblastoma multiforme. Strahlentherapie und Onkologie. 2014;190(10):933-938. https://doi.org/10.1007/s00066-014-0696-z
Shin M, Yang EG, Song HK, Jeon H. Insulin activates EGFR by stimulating its interaction with IGF-1R in low-EGFR-expressing TNBC cells. BMB Reports. 2015;48(6):342-347. https://doi.org/10.5483/bmbrep.2015.48.6.157
Leong HS, Robertson AE, Stoletov K, Leith SJ, Chin CA, Chien AE, Hague MN, Ablack A, Carmine-Simmen K, McPherson VA, Postenka CO, Turley EA, Courtneidge SA, Chambers AF, Lewis JD. Invadopodia are required for cancer cell extravasation and are a therapeutic target for metastasis. Cell Reports. 2014;8:1558-1570. https://doi.org/10.1016/j.celrep.2014.07.050
Song Y, Luo Q, Long H, Hu Z, Que T, Zhang X, Li Z, Wang G, Yi L, Liu Z, Fang W, Qi S. Alpha-enolase as a potential cancer prognostic marker promotes cell growth, migration, and invasion in glioma. Molecular Cancer. 2014;13:65. https://doi.org/10.1186/1476-4598-13-65
Zecchin A, Borgers G, Carmeliet P. Endothelial cells and cancer cells: metabolic partners in crime? Current Opinion in Hematology. 2015;22(3):234-242. https://doi.org/10.1097/MOH.0000000000000138
Mims J, Bansal N, Bharadwaj MS, Chen X, Molina AJ, Tsang AW, Furdui CM. Energy metabolism in a matched model of radiation resistance for head and neck squamous cell cancer. Radiation Research. 2015;183(3):291-304. https://doi.org/10.1667/RR13828.1
Grossman A, Beloosesky Y, Schlesinger A, Gafter-Gvili A, Koren-Morag N, Meyerovitch J, Weiss A. The association between glycated hemoglobin levels and mortality in non-diabetic elderly subjects. European Journal of Internal Medicine. 2016;27:57-61. https://doi.org/10.1016/j.ejim.2015.10.010
Joshu CE, Prizment AE, Dluzniewski PJ, Menke A, Folsom AR, Coresh J, Yeh HC, Brancati FL, Platz EA, Selvin E. Glycated Hemoglobin and Cancer Incidence and Mortality in the Atherosclerosis in Communities (ARIC) Study, 1990-2006. International Journal of Cancer. 2012;131(7):1667-1677. First published: 13 December 2011. https://doi.org/10.1002/ijc.27394
Hygino da Cruz LC, Rodriguez I, Domingues RC, Gasparetto EL, Sorensen AG. Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. AJNR. American Journal of Neuroradiology. 2011;32(11):1978-85. https://doi.org/10.3174/ajnr.A2397